Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanara MedTech (SMTI) Capital Expenditures (2016 - 2025)

Sanara MedTech (SMTI) has disclosed Capital Expenditures for 11 consecutive years, with $1.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Capital Expenditures rose 11547.79% year-over-year to $1.1 million, compared with a TTM value of $4.6 million through Sep 2025, up 2355.77%, and an annual FY2024 reading of $205848.0, down 22.39% over the prior year.
  • Capital Expenditures was $1.1 million for Q3 2025 at Sanara MedTech, down from $1.8 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.8 million in Q2 2025 and bottomed at $4391.0 in Q1 2021.
  • Average Capital Expenditures over 5 years is $280708.8, with a median of $53364.0 recorded in 2022.
  • The sharpest move saw Capital Expenditures tumbled 94.66% in 2024, then surged 11547.79% in 2025.
  • Year by year, Capital Expenditures stood at $141710.0 in 2021, then plummeted by 62.34% to $53364.0 in 2022, then grew by 1.71% to $54276.0 in 2023, then skyrocketed by 32.97% to $72172.0 in 2024, then surged by 1368.0% to $1.1 million in 2025.
  • Business Quant data shows Capital Expenditures for SMTI at $1.1 million in Q3 2025, $1.8 million in Q2 2025, and $1.7 million in Q1 2025.